Dec-poc pmpa
CAS: 1422284-17-0
Ref. 3D-XGC28417
| 1mg | To inquire | |
| 5mg | To inquire | |
| 10mg | To inquire | |
| 25mg | To inquire | |
| 50mg | To inquire |
Product Information
- 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, 1-ethyl 9-(1-Methylethyl) ester, 5-oxide
- 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]-, 1-ethyl 9-(1-methylethyl) ester, 5-oxide, (2E)-2-butenedioate (1:1)
Dec-poc pmpa is an oral prodrug that exhibits potent antiviral activity against HIV. It is rapidly converted to its active form, tenofovir alafenamide hemifumarate, in the presence of hydrochloric acid. Dec-poc pmpa has excellent pharmacokinetic properties, resulting in sustained plasma levels and enhanced bioavailability compared to other pharmaceutical preparations of tenofovir. This prodrug undergoes a phase transfer reaction in the body, allowing for efficient conversion to the active antiretroviral agent. Additionally, Dec-poc pmpa has been formulated to minimize impurities and contains an acid-binding agent to reduce potential renal biomarkers associated with tenofovir administration. Its mechanism of action involves inhibiting viral replication by targeting adenine residues in viral DNA synthesis.
Chemical properties
Technical inquiry about: 3D-XGC28417 Dec-poc pmpa
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
